Union Savings Bank Reduces Stock Position in Johnson & Johnson (NYSE:JNJ)

Union Savings Bank reduced its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 11.3% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 6,936 shares of the company’s stock after selling 883 shares during the quarter. Union Savings Bank’s holdings in Johnson & Johnson were worth $1,014,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. LCM Capital Management Inc raised its stake in Johnson & Johnson by 1.5% during the second quarter. LCM Capital Management Inc now owns 10,600 shares of the company’s stock valued at $1,549,000 after buying an additional 159 shares in the last quarter. Hilltop Partners LLC boosted its holdings in shares of Johnson & Johnson by 24.5% in the 2nd quarter. Hilltop Partners LLC now owns 10,850 shares of the company’s stock valued at $1,586,000 after buying an additional 2,138 shares during the period. Family Asset Management LLC raised its stake in Johnson & Johnson by 2.8% during the second quarter. Family Asset Management LLC now owns 3,345 shares of the company’s stock worth $489,000 after acquiring an additional 91 shares during the period. D.A. Davidson & CO. boosted its stake in Johnson & Johnson by 2.1% in the second quarter. D.A. Davidson & CO. now owns 582,121 shares of the company’s stock valued at $85,082,000 after acquiring an additional 11,986 shares during the period. Finally, MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH raised its position in shares of Johnson & Johnson by 38.1% during the 2nd quarter. MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH now owns 4,105 shares of the company’s stock worth $600,000 after purchasing an additional 1,132 shares during the period. Institutional investors own 69.55% of the company’s stock.

Wall Street Analysts Forecast Growth

JNJ has been the subject of several recent research reports. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Friday, August 16th. Daiwa Capital Markets lowered shares of Johnson & Johnson from an “outperform” rating to a “neutral” rating and decreased their target price for the company from $160.00 to $150.00 in a research report on Tuesday, July 23rd. Cantor Fitzgerald restated an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a research report on Tuesday. Daiwa America lowered Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 23rd. Finally, The Goldman Sachs Group dropped their price target on Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating on the stock in a report on Friday, July 19th. Seven equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Johnson & Johnson currently has an average rating of “Moderate Buy” and an average price target of $173.21.

Insiders Place Their Bets

In other Johnson & Johnson news, VP Robert J. Decker sold 5,635 shares of the stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $165.06, for a total value of $930,113.10. Following the completion of the sale, the vice president now directly owns 18,973 shares in the company, valued at $3,131,683.38. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Trading Up 0.8 %

Shares of NYSE JNJ opened at $167.16 on Wednesday. The company’s 50 day simple moving average is $156.42 and its 200 day simple moving average is $153.60. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.07 and a quick ratio of 0.85. The firm has a market capitalization of $402.30 billion, a P/E ratio of 10.42, a P/E/G ratio of 2.73 and a beta of 0.52. Johnson & Johnson has a fifty-two week low of $143.13 and a fifty-two week high of $167.81.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Wednesday, July 17th. The company reported $2.82 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.71 by $0.11. The firm had revenue of $22.45 billion for the quarter, compared to analysts’ expectations of $22.33 billion. Johnson & Johnson had a return on equity of 36.60% and a net margin of 46.34%. The company’s revenue was up 4.3% compared to the same quarter last year. During the same quarter last year, the business earned $2.80 earnings per share. On average, analysts predict that Johnson & Johnson will post 10.02 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Tuesday, August 27th will be given a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a dividend yield of 2.97%. The ex-dividend date is Tuesday, August 27th. Johnson & Johnson’s dividend payout ratio is currently 30.92%.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.